← brief for 2026-09-11 · Slowing decline

Sparsentan - SGLT2 inhibitor combination therapy in trials of IgA nephropathy.

Key takeaways

Sparsentan is a drug that blocks two separate signals that raise pressure inside the kidney filters. This report tests it alongside SGLT2 inhibitors, diabetes drugs that also protect kidneys, in people with IgA nephropathy, a disease where the immune system damages the filters. Both drugs cut protein in the urine, the main sign of damage in this disease, and the report asks whether the pair is safe and works together. It draws on SPARTACUS, a phase 2 open-label study, plus an extension of the larger PROTECT trial; the number of people and the follow-up time are not stated in the abstract available here.

Who did this work

Ayoub I · Alperovich G · Komers R · Kooienga LA · Mercer A · Moody S · Prkačin I · Rovin BH · Siktel H · Tang SCW

Source

Article · PubMed, the drug frontier · 2026 Sep 11
https://pubmed.ncbi.nlm.nih.gov/42726023/